Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma - Trial NCT06405321
Access comprehensive clinical trial information for NCT06405321 through Pure Global AI's free database. This phase not specified trial is sponsored by Guangxi Medical University and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Guangxi Medical University
Timeline & Enrollment
N/A
Jan 01, 2019
Dec 31, 2024
Primary Outcome
Overall survival
Summary
This multicenter retrospective study which included patients with hepatocellular carcinoma
 (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options
 and the best benefit group.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06405321
Non-Device Trial